Comparison of the Efficacy and Safety of Dronedarone and Amiodarone for Preventing Atrial Fibrillation Recurrence After Catheter Ablation: A Meta-Analysis of Reconstructed Time-to-Event Data

Presenter: Abdalhakim Shubietah.

Recurrence of atrial fibrillation (AF) remains common after catheter ablation. This meta-analysis compared dronedarone with amiodarone after ablation using individual patient time-to-event data reconstructed from published Kaplan-Meier curves. Four studies involving 887 patients were included. AF recurrence did not differ significantly between agents (hazard ratio [HR] 1.06, 95% confidence interval [CI] 0.75-1.50, P = 0.74), nor did blanking-period atrial tachyarrhythmia recurrence (risk ratio [RR] 1.12, P = 0.40), bradycardia (RR 0.98, P = 0.96), any drug-related adverse events (AEs) (RR 1.42, P = 0.64) or stroke (RR 0.51, P = 0.66). Dronedarone, however, carried significantly higher risks of gastrointestinal AEs (RR 7.72, 95% CI 2.10-28.37, P = 0.002) and dermatological AEs (RR 4.20, 95% CI 1.06-16.53, P = 0.04). The two drugs thus showed comparable efficacy against post-ablation AF recurrence and similar overall safety, with dronedarone associated with more gastrointestinal and dermatological AEs.

American Heart Association (AHA) Scientific Sessions 2026, November 6–9, Chicago, Illinois







Other Conference Highlights